Jazz Pharma Wards Off Epidiolex Patent Challenges, Hellenic Fights for Survival in Court, & OCT Rebrands to Octavian - Business of Cannabis

Business of Cannabis

Factuality

Ownership

Jazz Pharma Wards Off Epidiolex Patent Challenges, Hellenic Fights for Survival in Court, & OCT Rebrands to Octavian - Business of Cannabis

Jazz Pharmaceuticals   Jazz Pharmaceuticals has seen its market capitalisation increase by around $800m this week, after a 10% increase in its stock value. The pharmaceutical giant produces and owns the rights to Epidiolex, which, according to Prohibition Partners’ Pharmaceutical Cannabis Report, accounted for over three quarters of the entire pharmaceutical cannabis market as of 2023. Earlier this week, Jazz dismissed a patent claim against Apo…